2025.08.19

Korea’s Dong-A ST has launched its Stelara (ustekinumab) biosimilar Imuldosa in the United States through partners Intas Pharmaceuticals and Accord Biopharma, the company said Tuesday.

The drug, developed with Japan’s Meiji Seika Pharma, is approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Janssen’s Stelara generated $21.55 billion in global sales in 2024, according to IQVIA.

Imuldosa is already available in 14 countries, including Germany, the U.K. and Spain, and has marketing approval in Saudi Arabia, Qatar and the UAE.

Dong-A ST transferred development and commercialization rights for the project in 2020 and in 2021 signed a global out-licensing deal with Intas, which is rolling out the biosimilar through its Accord subsidiaries in the U.S., Europe, the U.K. and Canada.

출처 : KBR(https://www.koreabiomed.com)